Duke University School of Medicine, Durham, North Carolina, USA.
Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.
Neuro Oncol. 2024 Jun 3;26(6):1152-1162. doi: 10.1093/neuonc/noad261.
Laser interstitial thermal therapy (LITT) of intracranial tumors or radiation necrosis enables tissue diagnosis, cytoreduction, and rapid return to systemic therapies. Ablated tissue remains in situ, resulting in characteristic post-LITT edema associated with transient clinical worsening and complicating post-LITT response assessment.
All patients receiving LITT at a single center for tumors or radiation necrosis from 2015 to 2023 with ≥9 months of MRI follow-up were included. An nnU-Net segmentation model was trained to automatically segment contrast-enhancing lesion volume (CeLV) of LITT-treated lesions on T1-weighted images. Response assessment was performed using volumetric measurements.
Three hundred and eighty four unique MRI exams of 61 LITT-treated lesions and 6 control cases of medically managed radiation necrosis were analyzed. Automated segmentation was accurate in 367/384 (95.6%) images. CeLV increased to a median of 68.3% (IQR 35.1-109.2%) from baseline at 1-3 months from LITT (P = 0.0012) and returned to baseline thereafter. Overall survival (OS) for LITT-treated patients was 39.1 (9.2-93.4) months. Lesion expansion above 40% from volumetric nadir or baseline was considered volumetric progression. Twenty-one of 56 (37.5%) patients experienced progression for a volumetric progression-free survival of 21.4 (6.0-93.4) months. Patients with volumetric progression had worse OS (17.3 vs 62.1 months, P = 0.0015).
Post-LITT CeLV expansion is quantifiable and resolves within 6 months of LITT. Development of response assessment criteria for LITT-treated lesions is feasible and should be considered for clinical trials. Automated lesion segmentation could speed the adoption of volumetric response criteria in clinical practice.
激光间质热疗(LITT)治疗颅内肿瘤或放射性坏死可进行组织诊断、细胞减灭和快速恢复全身治疗。消融的组织仍留在原处,导致与短暂临床恶化相关的特征性 LITT 后水肿,并使 LITT 后反应评估复杂化。
纳入 2015 年至 2023 年在一家中心接受 LITT 治疗的肿瘤或放射性坏死患者,共 61 例 LITT 治疗病变,且至少有 9 个月的 MRI 随访。使用 nnU-Net 分割模型自动分割 LITT 治疗病变 T1 加权图像的增强病变体积(CeLV)。使用容积测量进行反应评估。
共分析了 61 例 LITT 治疗病变和 6 例经医学管理的放射性坏死对照病例的 384 个独特 MRI 检查。367/384(95.6%)图像的自动分割准确。CeLV 在 LITT 后 1-3 个月增加至基线的中位数 68.3%(IQR 35.1-109.2%)(P=0.0012),此后恢复至基线。LITT 治疗患者的总生存期(OS)为 39.1(9.2-93.4)个月。容积最低点或基线之上的病变扩张超过 40%被认为是容积进展。56 例患者中有 21 例(37.5%)发生进展,容积无进展生存期为 21.4(6.0-93.4)个月。发生容积进展的患者 OS 更差(17.3 与 62.1 个月,P=0.0015)。
LITT 后 CeLV 扩张是可量化的,并在 LITT 后 6 个月内消退。制定 LITT 治疗病变的反应评估标准是可行的,应考虑用于临床试验。自动病变分割可以加速容积反应标准在临床实践中的采用。